Sign in

CIK 0000882796

  • Large accelerated filer

BIOCRYST PHARMACEUTICALS INC

Sign in to watch
Ticker
BCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
621413174
Phone
+1 919-859-1302
Business address
4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-12-19 Doyle Anthony Chief Financial Officer Grant or award +120,700 380,328
2024-12-19 Doyle Anthony Chief Financial Officer Shares withheld for taxes −2,461 $7.39 $18K 377,867
2024-12-19 Doyle Anthony Chief Financial Officer Grant or award · Emp. Stock Option (Right to Buy) +250,100 250,100
2024-12-14 Doyle Anthony Chief Financial Officer Shares withheld for taxes −7,890 $7.53 $59K 259,628
2024-05-14 Doyle Anthony Chief Financial Officer Purchase +36,300 $5.57 $202K 266,744
2023-12-19 Doyle Anthony Chief Financial Officer Shares withheld for taxes −2,482 $6.05 $15K 227,444
2023-12-14 Doyle Anthony Chief Financial Officer Grant or award +34,000 235,401
2023-12-14 Doyle Anthony Chief Financial Officer Shares withheld for taxes −5,475 $6.43 $35K 229,926
2023-12-14 Doyle Anthony Chief Financial Officer Grant or award · Emp. Stock Option (Right to Buy) +158,500 158,500
2022-12-19 Doyle Anthony Chief Financial Officer Grant or award +34,000 197,966
2022-12-19 Doyle Anthony Chief Financial Officer Grant or award · Emp. Stock Option (Right to Buy) +158,500 158,500
2022-12-15 Doyle Anthony Chief Financial Officer Sale −5,700 $10.90 $62K 163,966
2021-12-14 Doyle Anthony Chief Financial Officer Grant or award +75,000 168,719
2021-12-14 Doyle Anthony Chief Financial Officer Grant or award +115,000 208,719
2021-12-14 Doyle Anthony Chief Financial Officer Grant or award · Emp. Stock Option (Right to Buy) +164,000 164,000
2021-11-23 Doyle Anthony Chief Financial Officer Purchase +35,258 $12.48 $440K 93,719
2020-12-15 Doyle Anthony Chief Financial Officer Grant or award · Emp. Stock Option (Right to Buy) +332,500 332,500
2020-08-11 Doyle Anthony Chief Financial Officer Purchase +54,000 $4.08 $220K 54,000
2020-04-30 Doyle Anthony Chief Financial Officer Grant or award · Emp. Stock Option (Right to Buy) +600,000 600,000

Page 1 of 1 · 19 trades